I hope everyone read my positive write-up yesterday of Exact Sciences (EXAS - Get Report) and its revamped stool-based gene test for colon cancer. Amazing, I know, but I am capable of being bullish on a healthcare stock. I sincerely think Exact is a compelling turnaround story.Of course, even my positive columns get pushback. Rick A. doesn't think Exact's efforts to improve its stool-based test will matter much because patients still don't want to deal with their stool.
Biotech Stock Mailbag: GenVec
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.